Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

55.95
-15.7000-21.91%
Post-market: 58.412.46+4.40%19:58 EST
Volume:5.00M
Turnover:256.84M
Market Cap:2.11B
PE:-10.31
High:73.97
Open:71.63
Low:40.00
Close:71.65
52wk High:99.50
52wk Low:30.82
Shares:37.75M
Float Shares:32.58M
Volume Ratio:11.85
T/O Rate:15.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4247
EPS(LYR):-3.9613
ROE:-34.78%
ROA:-22.61%
PB:3.68
PE(LYR):-14.12

Loading ...

Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval

Dow Jones
·
Feb 14

BUZZ-Disc Medicine dives as FDA declines to approve rare disease drug

Reuters
·
Feb 14

Disc Medicine down 32% to $49 after confirming rejection letter from FDA

TIPRANKS
·
Feb 14

Disc Medicine confirms complete response letter from FDA for bitopertin

TIPRANKS
·
Feb 14

Disc Medicine says issue raised by FDA ‘readily addressable’

TIPRANKS
·
Feb 14

US FDA declines to approve Disc Medicine's rare disease drug

Reuters
·
Feb 14

Disc Medicine Inc: Plans to Request a Type a Meeting to Review Our Approach With FDA

THOMSON REUTERS
·
Feb 14

Disc Medicine Inc - FDA Requires Results From Phase 3 Apollo Study for Decision

THOMSON REUTERS
·
Feb 14

Disc Medicine Inc: FDA Acknowledged That Aurora and Beacon Provided Sufficient Evidence That Bitopertin Significantly Lowers Ppix

THOMSON REUTERS
·
Feb 14

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

GlobeNewswire
·
Feb 14

Disc Medicine drops 21% to $56.53 in afternoon plunge

TIPRANKS
·
Feb 14

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:31 PM

Reuters
·
Feb 14

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Disc Medicine (IRON)

TIPRANKS
·
Feb 11

Press Release: CHAMPION IRON REPORTS ITS FY2026 THIRD QUARTER RESULTS AND ADVANCES THE DRPF PROJECT AS PLANNED

Dow Jones
·
Jan 29

Disc Medicine Chief Legal Officer Rahul Khara Reports Disposal of Common Shares

Reuters
·
Jan 22

Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus

Simply Wall St.
·
Jan 18

Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

Benzinga
·
Jan 17

Disc Medicine: Bitopertin’s Accelerated Approval Path and FDA Timing Support Buy Rating and $118 Target

TIPRANKS
·
Jan 16

EXCLUSIVE-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

Reuters
·
Jan 16

Sector Update: Health Care Stocks Softer in Afternoon Trading

MT Newswires Live
·
Jan 16